|Rigel Announces Presentation at Three Investor Conferences|
SOUTH SAN FRANCISCO, Calif., June 3, 2010 /PRNewswire via COMTEX/ --Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, chairman and chief executive officer, and Ryan Maynard, executive vice president and chief financial officer of Rigel, will present at three separate investor conferences in June. Details of each conference are as follows:
Jefferies Global Life Sciences Conference New York City, NY June 10, 8:00 a.m. EST Speaker: James M. Gower Think Equity's Mid Year Check-Up on Healthcare Conference New York City, NY June 16, 3:30 p.m. EST Speaker: Ryan Maynard Fifth Annual Piper Jaffray Europe Conference London, England June 22, 9:30 a.m. BST Speaker: James M. Gower
All three presentations will be webcast. To access the live audio webcast or subsequent archived recording, log on to http://www.rigel.com. Please connect to Rigel's website several minutes prior to the start of the live webcast to ensure adequate time for any software download that may be necessary.
About Rigel (www.rigel.com)
Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory/autoimmune, muscle and metabolic diseases. Rigel's pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market its product candidates. Current product development programs include R788, an oral Syk inhibitor that is expected to enter Phase 3 clinical trials for rheumatoid arthritis in 2010, and R343, an inhaled Syk inhibitor that is in clinical trials for asthma.
Contact: Ryan Maynard Phone: 650.624.1284 Email: firstname.lastname@example.org
SOURCE Rigel Pharmaceuticals, Inc.